News

VIPC’s Robert Stolle Announces Plans to Step Down From His Role as President and CEO

As CEO, Bob Stolle led Virginia’s consolidation of several innovation and entrepreneurship programs into the newly established VIPC. This consolidation expanded and coordinated programs that provide support for Virginia’s entrepreneurs, tech startups, research commercialization, regional ecosystems, and new industry sectors such as Advanced Air Mobility and Smart Communities.

“Having the privilege of leading VIPC over the last three years has been the most rewarding experience of my professional career” Stolle said. “VIPC has a staff of exceptionally talented and experienced professionals. I’m very proud of where we are as a team, but I believe this is a good time to pass the baton to the next generation of leadership for innovation in Virginia”.

“The Commonwealth has benefited greatly and will continue to benefit for years to come from Bob’s many years of investing his considerable talents, time, and exemplary service,” said Caren Merrick, Secretary of Commerce and Trade and Vice Chair of VIPC.

“Under Bob’s leadership, VIPC has forged a series of integrated programs to help entrepreneurs bring their technologies to commercialization, whether the technology originates in one of Virginia’s academic institutions or in the private sector. As an entrepreneur myself, I know that these programs make a real difference in the success of our emerging and growing tech enterprise,” said Barbara D. Boyan, PhD, Chair of the VIPC Board of Directors and Executive Director of the Institute for Engineering and Medicine at Virginia Commonwealth University.

Joseph Benevento, Virginia Deputy Secretary of Commerce & Trade, will assume the role of Interim CEO beginning in September, while the VIPC Board recruits a permanent CEO. Bob Stolle will stay on in an advisory role to assist in the transition until at least the end of October.

“I’m very grateful to the VIPC Board of Directors and to the Youngkin Administration for their trust, support, and for the opportunity to serve the Commonwealth of Virginia” Stolle said.

Learn more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and